Report Scope:
This report discusses the key trends shaping the global cell therapy biomanufacturing market, exploring factors that drive or hinder growth while providing valuable insights for stakeholders and potential newcomers. It examines R&D investment, heightened competition, and emerging technologies steering market dynamics. Moreover, the report assesses how advancements, product launches, and governmental initiatives impact future market trajectories. It also scrutinizes corporate actions like mergers, acquisitions, and partnerships. Additionally, the report evaluates the efficacy of various strategies in light of evolving technologies, intensifying competition, and shifting consumer demands.

Report Includes:

  • 17 data tables and 25 additional tables
  • Analysis of the global markets for cell therapy biomanufacturing
  • Analyses of global market trends, with market revenue data from 2022, estimates for 2023, forecasts for 2024 and projected CAGRs through 2029
  • Estimates of the current market size and revenue prospects, along with a market share analysis by product type, application, end user and region
  • Facts and figures pertaining to the market dynamics, technological advances, product launches, regulatory scenarios, and the expected impact of macroeconomic factors
  • An analysis of patents and emerging technologies
  • Overview of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies’ ESG score rankings and their ESG practices


- An analysis of the industry structure, including companies’ market shares, merger and acquisition activity, and venture funding

  • Profiles of the leading companies, including Thermo Fisher Scientific Inc., Bristol-Myers Squibb Co., Lonza, Merck KGaA, andBioSenic SA